(ALK-B) ALK-Abelló - CO
Sector: Healthcare | Industry: Biotechnology | Exchange: CO (Denmark) | Market Cap: 58.321m DKK | Total Return: 42.7% in 12m
Avg Turnover: 42.2M
EPS Trend: 98.0%
Qual. Beats: 1
Rev. Trend: 99.6%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
Confidence
ALK-Abelló A/S is a Denmark-based biotechnology company specializing in allergy immunotherapy (AIT) and emergency treatments for anaphylaxis. The company develops and manufactures sublingual tablets, injections, and drops designed to treat the underlying causes of respiratory allergies, such as pollen and house dust mites, rather than just managing symptoms.
The business model relies on a global distribution network and strategic partnerships, such as collaborations with Torii Pharmaceutical and Dr. Reddys Laboratories, to commercialize its portfolio across Europe, North America, and Asia. In the biotechnology sector, this tablet-based immunotherapy represents a shift from traditional subcutaneous injections toward more convenient, patient-administered treatments that improve long-term adherence.
Beyond its core pharmaceutical products, ALK-Abelló integrates digital health platforms and diagnostic tools, including skin prick tests and the klarify.me engagement tool, to support the full patient journey. The company also maintains a presence in the emergency medicine market through the production of adrenaline autoinjectors and nasal sprays for life-threatening allergic reactions.
- Tablet portfolio adoption drives revenue growth and margin expansion
- US market penetration of sublingual immunotherapy determines long-term valuation
- Research and development pipeline progress in food allergy treatments
- Strategic shift toward digital patient engagement platforms scales market share
| Net Income: 1.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 19.87 > 1.0 |
| NWC/Revenue: 49.25% < 20% (prev 29.82%; Δ 19.43% < -1%) |
| CFO/TA 0.24 > 3% & CFO 2.19b > Net Income 1.28b |
| Net Debt (-889.0m) to EBITDA (2.12b): -0.42 < 3 |
| Current Ratio: 3.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.6m) vs 12m ago 0.15% < -2% |
| Gross Margin: 67.76% > 18% (prev 64.45%; Δ 3.31% > 0.5%) |
| Asset Turnover: 75.08% > 50% (prev 69.71%; Δ 5.37% > 0%) |
| Interest Coverage Ratio: 77.13 > 6 (EBIT TTM 1.77b / Interest Expense TTM 23.0m) |
| A: 0.35 (Total Current Assets 4.67b - Total Current Liabilities 1.43b) / Total Assets 9.29b |
| B: 0.70 (Retained Earnings 6.53b / Total Assets 9.29b) |
| C: 0.20 (EBIT TTM 1.77b / Avg Total Assets 8.74b) |
| D: 2.41 (Book Value of Equity 6.57b / Total Liabilities 2.72b) |
| Altman-Z'' = 8.47 = AAA |
| DSRI: 1.09 (Receivables 1.20b/961.0m, Revenue 6.56b/5.71b) |
| GMI: 0.95 (GM 64.45% / 67.76%) |
| AQI: 0.81 (AQ_t 0.25 / AQ_t-1 0.31) |
| SGI: 1.15 (Revenue 6.56b / 5.71b) |
| TATA: -0.10 (NI 1.28b - CFO 2.19b) / TA 9.29b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at DKK 255.40 with a total of 181,098 shares traded.
Over the past week, the price has changed by -5.13%,
over one month by +2.08%,
over three months by +21.62% and
over the past year by +42.65%.
ALK-Abelló has no consensus analysts rating.
P/E Trailing = 45.3012
P/E Forward = 68.9655
P/S = 8.8891
P/B = 8.75
P/EG = 9.8673
Revenue TTM = 6.56b DKK
EBIT TTM = 1.77b DKK
EBITDA TTM = 2.12b DKK
Long Term Debt = 147.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 61.0m DKK (from shortTermDebt, last quarter)
Debt = 656.0m DKK (from shortLongTermDebtTotal, last quarter) + Leases 246.0m
Net Debt = -889.0m DKK (calculated: Debt 656.0m - CCE 1.54b)
Enterprise Value = 57.4b DKK (58.3b + Debt 656.0m - CCE 1.54b)
Interest Coverage Ratio = 77.13 (Ebit TTM 1.77b / Interest Expense TTM 23.0m)
EV/FCF = 30.78x (Enterprise Value 57.4b / FCF TTM 1.87b)
FCF Yield = 3.25% (FCF TTM 1.87b / Enterprise Value 57.4b)
FCF Margin = 28.44% (FCF TTM 1.87b / Revenue TTM 6.56b)
Net Margin = 19.51% (Net Income TTM 1.28b / Revenue TTM 6.56b)
Gross Margin = 67.76% ((Revenue TTM 6.56b - Cost of Revenue TTM 2.12b) / Revenue TTM)
Gross Margin QoQ = 69.34% (prev 68.09%)
Tobins Q-Ratio = 6.18 (Enterprise Value 57.4b / Total Assets 9.29b)
Interest Expense / Debt = 3.51% (Interest Expense 23.0m / Debt 656.0m)
Taxrate = 26.65% (465.0m / 1.75b)
NOPAT = 1.30b (EBIT 1.77b * (1 - 26.65%))
Current Ratio = 3.25 (Total Current Assets 4.67b / Total Current Liabilities 1.43b)
Debt / Equity = 0.10 (Debt 656.0m / totalStockholderEquity, last quarter 6.57b)
Debt / EBITDA = -0.42 (Net Debt -889.0m / EBITDA 2.12b)
Debt / FCF = -0.48 (Net Debt -889.0m / FCF TTM 1.87b)
Total Stockholder Equity = 6.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.65% (Net Income 1.28b / Total Assets 9.29b)
RoE = 20.45% (Net Income TTM 1.28b / Total Stockholder Equity 6.26b)
RoCE = 27.69% (EBIT 1.77b / Capital Employed (Equity 6.26b + L.T.Debt 147.0m))
RoIC = 17.15% (NOPAT 1.30b / Invested Capital 7.59b)
WACC = 7.00% (E(58.3b)/V(59.0b) * Re(7.05%) + D(656.0m)/V(59.0b) * Rd(3.51%) * (1-Tc(0.27)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 15.56 | Cagr: -2.83%
[DCF] Terminal Value 77.97% ; FCFF base≈1.13b ; Y1≈1.29b ; Y5≈1.90b
[DCF] Fair Price = 146.5 (EV 28.6b - Net Debt -889.0m = Equity 29.5b / Shares 201.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.99 | EPS CAGR: 59.50% | SUE: 1.50 | # QB: 1
Revenue Correlation: 99.60 | Revenue CAGR: 13.58% | SUE: 1.47 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.50 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.50 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=6.58 | Chg30d=-0.32% | Revisions=+43% | GrowthEPS=+21.9% | GrowthRev=+15.2%
EPS next Year (2027-12-31): EPS=7.51 | Chg30d=-0.13% | Revisions=+14% | GrowthEPS=+14.1% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +43%